The renin–angiotensin–aldosterone system (RAAS) is a network of enzymes, signaling peptides, and hormones that regulates arterial blood pressure, sodium and potassium balance, and extracellular fluid volume. Its classical sequence begins when the kidney releases renin, which initiates the production of angiotensin II. Angiotensin II constricts blood vessels, changes renal sodium handling, stimulates thirst, and promotes secretion of aldosterone from the adrenal cortex. Aldosterone increases sodium reabsorption and potassium secretion in the distal nephron. Together, these actions help maintain circulation during reduced blood volume or diminished renal perfusion.
The system is essential to normal homeostasis, but sustained or inappropriate activation contributes to hypertension, heart failure, and progressive chronic kidney disease. It is therefore a major target of cardiovascular and kidney medicines. The familiar circulating cascade is only part of the system: tissues contain additional angiotensin-processing enzymes, receptor subtypes, and local signaling pathways whose effects depend on the organ and physiological setting.
Components and biochemical cascade
The starting substrate of the classical cascade is angiotensinogen, a circulating protein produced predominantly by the liver. Renin, an aspartyl protease, cleaves angiotensinogen to release angiotensin I, a peptide containing 10 amino acids. Angiotensin I has relatively little direct biological activity. Its principal importance is as a precursor of angiotensin II, an eight-amino-acid peptide formed when angiotensin-converting enzyme removes two amino acids from its carboxyl terminus. The classical sequence can be represented as
Angiotensin-converting enzyme (ACE) is a membrane-associated zinc metallopeptidase expressed on vascular endothelial cells and several epithelial surfaces, including the renal proximal tubule. The pulmonary circulation provides a large endothelial surface for conversion, but ACE is not confined to the lungs. It also degrades bradykinin, a peptide involved in vasodilation and vascular permeability. This dual function explains why inhibiting ACE affects more than angiotensin II formation: it also increases the availability of bradykinin and related peptides.
Angiotensin II acts through cell-surface receptors and is rapidly metabolized. Removal of its amino-terminal aspartate produces angiotensin III, which retains biological activity, including stimulation of aldosterone secretion. Further processing produces angiotensin IV and other fragments. These peptides are not simply inactive waste products; some have distinct binding sites or biological effects. Their relative importance varies between circulating blood and individual tissues, and the concentrations measured in plasma do not necessarily describe what is occurring within a kidney, blood vessel, or brain region.
A second major processing route involves angiotensin-converting enzyme 2 (ACE2), a carboxypeptidase that differs from ACE in substrate specificity and pharmacology. ACE2 can convert angiotensin II into angiotensin-(1–7), a seven-amino-acid peptide associated with signaling through the Mas receptor. It can also convert angiotensin I into angiotensin-(1–9), which can subsequently be processed further. Conventional ACE inhibitors do not directly inhibit ACE2. Other enzymes, including neprilysin, aminopeptidases, and chymase, provide additional routes of peptide formation or degradation. The RAAS is consequently better understood as a regulated network than as a single unbranched chain.
Renin secretion and its control
Renin is synthesized principally by granular cells in the juxtaglomerular apparatus, usually located in the wall of the afferent arteriole near its entry into the renal glomerulus. These cells have features of modified vascular smooth muscle cells and contain secretory granules. Renin is initially synthesized as preprorenin, processed to prorenin, and then converted to active renin by removal of a prosegment. Both active renin and prorenin can circulate, but assays of renin activity and assays of renin concentration measure different properties.
Three major inputs regulate renin release. First, reduced pressure or stretch in the renal afferent arteriolar region stimulates secretion through an intrarenal baroreceptor mechanism. Second, the macula densa, a specialized epithelial region adjoining the distal end of the thick ascending limb, senses tubular sodium chloride delivery through transport processes involving the NKCC2 cotransporter. Reduced sodium chloride delivery promotes signaling through cyclooxygenase-2-derived prostaglandins and other local mediators that stimulate renin release. Greater delivery favors adenosine-dependent signals that restrain release. Third, renal sympathetic nerves stimulate beta-1 adrenergic receptors on granular cells, increasing renin secretion through cyclic AMP-dependent pathways.
These mechanisms allow renin release to respond to different forms of circulatory stress. Blood loss, dehydration, and reduced cardiac output can all activate the system. Renin secretion reflects the circulation perceived by the kidney rather than total body water alone. In heart failure or advanced cirrhosis, extracellular fluid may be increased while effective arterial filling is reduced. The kidney can therefore activate sodium-retaining pathways despite peripheral edema or ascites. This distinction is central to understanding fluid-retaining disorders.
Negative feedback limits activation. Angiotensin II acting on AT1 receptors suppresses renin secretion directly, while restoration of perfusion pressure and sodium delivery provides additional restraint. Consequently, ACE inhibitors and angiotensin receptor blockers usually increase renin release by interrupting feedback, even while reducing downstream signaling. Direct renin inhibition can likewise increase measured renin concentration while suppressing its catalytic activity. A high renin concentration during treatment therefore does not necessarily indicate high angiotensin II production.
Renin also varies with posture, sodium intake, time of day, age, and medication exposure. Upright posture and sodium restriction generally increase renin, whereas high sodium intake suppresses it. These influences are physiologically appropriate, but they complicate comparisons between laboratory results obtained under different conditions.
Angiotensin receptors and cellular signaling
Most established cardiovascular and renal actions of angiotensin II are mediated by the angiotensin II type 1 receptor, usually abbreviated AT1. This receptor belongs to the G protein-coupled receptor family. In many target cells, activation couples to Gq/11 proteins, stimulates phospholipase C, generates inositol trisphosphate and diacylglycerol, and increases intracellular calcium. In vascular smooth muscle, these events promote contraction. AT1 receptors also engage other signaling pathways, including mitogen-activated protein kinases and beta-arrestin-associated pathways, allowing effects on cell growth, transport, and gene regulation.
The immediate vascular effect is increased arteriolar resistance. In the kidney, angiotensin II constricts both afferent and efferent arterioles, with efferent constriction particularly important at moderate concentrations and during reduced perfusion. This can help preserve glomerular capillary pressure even as renal blood flow falls. At higher levels or under different physiological conditions, the combined effects of vasoconstriction and mesangial contraction can reduce filtration. Angiotensin II also increases proximal tubular sodium reabsorption, including through stimulation of the sodium–hydrogen exchanger NHE3, and influences transport in more distal nephron segments.
AT1 signaling has effects extending beyond short-term pressure control. Persistent activation can stimulate reactive oxygen species production, inflammatory signaling, extracellular matrix deposition, and cellular hypertrophy. These processes help explain the relationship between chronic RAAS activation and fibrosis in the heart, kidney, and vasculature. Their importance depends on context: a pathway that supports perfusion during acute volume depletion can contribute to structural injury when chronically activated in hypertension or heart failure.
Angiotensin II also binds the AT2 receptor. AT2 expression is prominent during development and varies across adult tissues and disease states. Its signaling often involves phosphatases, nitric oxide, and cyclic GMP, and many experimental effects oppose AT1-mediated contraction or growth. However, describing AT2 as universally protective is too simple; receptor abundance, tissue location, and experimental conditions influence the response. The same caution applies to angiotensin-(1–7) and Mas signaling, which frequently promotes vasodilation and counter-regulates AT1-associated effects but does not function as a uniform mirror image of the classical pathway.
Angiotensin IV has a historically designated AT4 binding site associated with insulin-regulated aminopeptidase. Studies have explored effects on cognition, blood flow, and cellular signaling, although these mechanisms are less firmly established in routine clinical practice than AT1-mediated physiology. Receptor identity and location are therefore as important as peptide concentration in determining the biological response.
Aldosterone synthesis and renal electrolyte transport
Aldosterone is a steroid hormone produced mainly by cells of the zona glomerulosa, the outermost layer of the adrenal cortex. Its synthesis begins with cholesterol and proceeds through a series of mitochondrial and smooth endoplasmic reticulum reactions. The terminal steps depend on aldosterone synthase, encoded by CYP11B2. Angiotensin II stimulates these cells through AT1 receptors, increasing intracellular calcium and steroid synthesis. Elevated extracellular potassium independently stimulates aldosterone production by depolarizing glomerulosa cells and opening voltage-dependent calcium channels. Adrenocorticotropic hormone also has a stimulatory role, generally less important for sustained regulation.
Aldosterone acts principally through the intracellular mineralocorticoid receptor (MR). After binding its ligand, the receptor influences gene expression, altering the abundance or activity of proteins involved in electrolyte transport. In aldosterone-sensitive distal nephron segments, including the connecting tubule and collecting duct, it increases the capacity for sodium entry through the epithelial sodium channel, ENaC, and sodium extrusion through the basolateral sodium–potassium ATPase. Serum- and glucocorticoid-regulated kinase 1 contributes by reducing removal of ENaC from the cell surface through effects on the regulatory protein NEDD4-2.
Sodium reabsorption through ENaC makes the tubular lumen more electrically negative, favoring potassium secretion through apical potassium channels such as ROMK. Potassium excretion also depends on distal sodium delivery, tubular flow, and potassium availability; aldosterone concentration alone does not determine urinary potassium loss. Aldosterone additionally promotes hydrogen ion secretion in the distal nephron. Excess mineralocorticoid activity can therefore produce sodium retention, potassium depletion, and metabolic alkalosis, although these features need not all be present in every affected person.
The MR also binds cortisol, which circulates at much higher concentrations than aldosterone. Selectivity in epithelial target tissues is provided largely by 11-beta-hydroxysteroid dehydrogenase type 2, which converts cortisol to cortisone, a much weaker MR ligand. Inherited deficiency of this enzyme, or its inhibition by compounds derived from licorice, can produce apparent mineralocorticoid excess: hypertension, suppressed renin, and suppressed aldosterone despite increased MR activation.
Sustained aldosterone exposure does not normally cause unlimited sodium accumulation. A phenomenon termed aldosterone escape develops through increased pressure-dependent sodium excretion and other compensatory mechanisms. Potassium wasting may nevertheless persist. This explains why uncomplicated primary aldosteronism often causes hypertension without marked peripheral edema, whereas disorders with impaired effective circulation can sustain substantial fluid retention.
Integration with circulation, neural control, and tissue systems
RAAS activity operates alongside sympathetic signaling, vasopressin, natriuretic peptides, and intrinsic renal autoregulation. A simplified relationship connects arterial pressure with cardiac output and systemic vascular resistance:
Angiotensin II can increase resistance within minutes, while sodium retention expands extracellular fluid volume over longer periods and influences venous return and cardiac output. The equation describes a hemodynamic relationship rather than a complete control model: changes in one variable can evoke compensatory changes in the others.
Angiotensin II also acts on neural circuits controlling thirst, salt appetite, sympathetic activity, and vasopressin release. Circulating angiotensin II can influence circumventricular organs, including the subfornical organ and organum vasculosum of the lamina terminalis, whose vascular arrangement allows access to signals that do not readily cross the blood–brain barrier. These regions communicate with the hypothalamus and other autonomic centers. Vasopressin increases collecting-duct water permeability through aquaporin-2 trafficking, complementing the RAAS-mediated conservation of sodium. Sodium balance and water balance are thus coordinated but remain physiologically distinct.
Counter-regulatory systems restrain volume expansion. Atrial and B-type natriuretic peptides respond to cardiac wall stress and promote effects that include natriuresis, vasodilation, and suppression of renin or aldosterone secretion. Pressure natriuresis—the increase in renal sodium excretion as renal perfusion pressure rises—provides another important long-term constraint. In chronic hypertension and kidney disease, the relation between pressure and sodium excretion may shift, so a higher pressure is required to maintain sodium balance.
RAAS components are present within the kidney, heart, vascular wall, adrenal gland, adipose tissue, and nervous system. The term tissue RAAS refers to local production, processing, uptake, or action of system components rather than a wholly independent miniature copy of the circulating cascade in every organ. In the kidney, locally generated or accumulated angiotensin II can affect tubular transport and vascular function even when circulating measurements are not markedly elevated. Uptake of circulating peptides and intracellular trafficking further complicate the distinction between local and systemic sources.
Intracellular angiotensin signaling and the prorenin receptor have also been studied. The protein commonly called the prorenin receptor, encoded by ATP6AP2, has cellular functions associated with vacuolar proton ATPase biology as well as interactions with renin and prorenin. These overlapping roles make it difficult to attribute every experimental effect to a conventional hormone–receptor mechanism. Plasma hormone measurements consequently capture only selected aspects of a distributed regulatory network.
Roles in cardiovascular, kidney, and endocrine disease
In primary hypertension, RAAS activity is heterogeneous. Some people have relatively high renin, others low renin, and many have values within laboratory reference ranges. A “normal” concentration may still be inappropriate for the prevailing blood pressure, sodium status, or extracellular volume. Hypertension cannot therefore be classified simply as the presence or absence of an elevated circulating RAAS measurement. Genetic variation, sympathetic activity, kidney sodium handling, and vascular structure all contribute to the relationship between the system and sustained blood pressure.
Renal artery narrowing provides a clearer mechanism. Reduced pressure beyond a stenosis can stimulate renin release from the affected kidney, increasing angiotensin II and aldosterone. In unilateral disease, the other kidney may excrete additional sodium in response to the higher systemic pressure. With bilateral severe disease, or disease affecting a solitary functioning kidney, maintenance of filtration may depend more strongly on angiotensin II-mediated efferent arteriolar tone. Anatomical stenosis alone, however, does not establish that it is the cause of a person’s hypertension.
In heart failure, reduced forward output and altered arterial filling activate renal and sympathetic mechanisms that increase renin secretion. Initially, vasoconstriction and sodium retention support perfusion pressure. Persistently, they increase afterload, congestion, and cardiac workload. Angiotensin II and aldosterone also participate in remodeling and fibrosis. The benefits of RAAS-blocking medicines in selected forms of heart failure reflect effects on both hemodynamics and longer-term disease progression, rather than simple removal of excess fluid.
In diabetic and other proteinuric kidney diseases, intraglomerular pressure and altered glomerular barrier function contribute to albumin leakage. RAAS activation can intensify these processes and promote inflammatory and fibrotic injury. Reducing angiotensin II signaling can lower intraglomerular pressure and albuminuria, which helps explain why these medicines have kidney-protective effects in appropriate populations. An early decline in filtration after treatment can be hemodynamic rather than evidence of direct toxicity, although larger changes can signal clinically important perfusion or volume problems. Kidney disease also changes potassium handling, altering the safety profile of RAAS blockade.
Primary aldosteronism differs from secondary activation because aldosterone production is relatively autonomous and renin is suppressed. Causes include bilateral adrenal disease and aldosterone-producing adrenal adenomas. Hypokalemia is a recognized feature but is absent in many cases. Conversely, reduced aldosterone synthesis or action can cause hyperkalemia and a tendency toward metabolic acidosis. Hyporeninemic hypoaldosteronism occurs particularly in association with diabetes mellitus and kidney disease, while primary adrenal insufficiency can impair aldosterone production directly. Rare inherited abnormalities affecting renin, angiotensinogen, ACE, or the AT1 receptor can disrupt fetal renal development and cause renal tubular dysgenesis.
Laboratory assessment and diagnostic interpretation
RAAS assessment usually measures selected circulating components rather than the activity of the entire system. Plasma renin activity estimates the rate at which a sample generates angiotensin I under specified laboratory conditions. Direct renin concentration measures immunoreactive renin using an assay calibrated for concentration. The results are not interchangeable: renin activity depends partly on substrate availability and assay conditions, whereas direct assays quantify the enzyme rather than its net catalytic output. Direct renin inhibitors particularly illustrate the difference because they can suppress activity while increasing renin concentration through feedback.
Aldosterone is measured in blood or, in selected investigations, urine. A central application is the aldosterone-to-renin ratio in the evaluation of primary aldosteronism. A high ratio is meaningful only in relation to the absolute aldosterone and renin values, the assay method, and the clinical setting. Very low renin can produce a numerically high ratio even when aldosterone is not convincingly elevated. No single numerical cutoff applies universally across plasma renin activity, direct renin concentration, immunoassay-based aldosterone measurements, and mass-spectrometric aldosterone measurements.
Sampling conditions substantially influence results. Posture, time of collection, sodium intake, potassium concentration, kidney function, and multiple medications affect renin or aldosterone. Low potassium can suppress aldosterone secretion and obscure biochemical evidence of excess production. Beta blockers commonly suppress renin, while diuretics, ACE inhibitors, and angiotensin receptor blockers can increase it. Mineralocorticoid receptor antagonists alter the feedback system and may complicate interpretation. These effects are part of the biological meaning of a result, not merely technical laboratory interference.
When primary aldosteronism is investigated, suppression procedures may assess whether aldosterone remains inappropriately elevated during interventions that normally reduce its secretion. The choice and interpretation of such testing depend on the clinical circumstances. Adrenal computed tomography describes anatomy but cannot reliably establish which adrenal gland is secreting excess aldosterone. A visible nodule may be nonfunctioning, and a small functioning lesion may not be apparent. Adrenal venous sampling can compare secretion from the two glands when determining laterality is relevant.
Angiotensin peptide profiling by mass spectrometry has expanded research into the system’s multiple branches. Measurement remains demanding because peptides are rapidly generated and degraded, including after blood collection. Sample handling, enzyme inhibition, and analytical methods can change the pattern detected. A circulating peptide concentration is therefore not a direct measure of receptor activation, tissue exposure, or total-body RAAS activity.
Pharmacological interruption and clinical evidence
Several medicine classes interrupt the system at different levels. ACE inhibitors, including captopril, enalapril, and lisinopril, reduce ACE-mediated formation of angiotensin II and decrease bradykinin degradation. Angiotensin receptor blockers (ARBs), including losartan, valsartan, and candesartan, selectively block AT1 receptors without directly inhibiting ACE. Aliskiren inhibits renin’s catalytic activity. Mineralocorticoid receptor antagonists, including spironolactone, eplerenone, and finerenone, act downstream at the aldosterone receptor rather than preventing angiotensin II formation. The classes therefore differ in both physiological effects and adverse effects.
ACE inhibitors and ARBs are established therapies for hypertension and have disease-modifying roles in specific cardiovascular and kidney conditions. The 1987 CONSENSUS trial demonstrated improved survival with enalapril in severe heart failure. The 1991 SOLVD treatment trial extended evidence to symptomatic heart failure with reduced left ventricular ejection fraction. In kidney disease associated with type 2 diabetes, the RENAAL and IDNT trials, both reported in 2001, supported renal benefits of losartan and irbesartan, respectively, in their studied populations. Such findings concern defined clinical groups and cannot be assumed to apply identically to every form of kidney disease or heart failure.
Mineralocorticoid receptor blockade provides a different intervention point. RALES, published in 1999, showed that adding spironolactone to then-standard treatment reduced mortality in selected patients with severe heart failure. Subsequent trials established roles for eplerenone in other reduced-ejection-fraction settings. FIDELIO-DKD, reported in 2020, and FIGARO-DKD, reported in 2021, demonstrated kidney and cardiovascular benefits of the nonsteroidal antagonist finerenone in selected populations with type 2 diabetes and chronic kidney disease. These trials also documented the importance of hyperkalemia as an adverse effect.
Combining pathways is not automatically beneficial. Sacubitril/valsartan combines neprilysin inhibition with AT1 blockade, augmenting natriuretic peptide-related effects while blocking angiotensin II signaling; PARADIGM-HF, reported in 2014, demonstrated benefit over enalapril in its studied population with reduced-ejection-fraction heart failure. In contrast, simultaneous blockade with an ACE inhibitor and an ARB, or addition of a direct renin inhibitor to other RAAS blockade in high-risk populations, has not generally produced a favorable balance of clinical benefits and harms. Trials including ONTARGET, ALTITUDE, and VA NEPHRON-D documented concerns involving hyperkalemia, hypotension, or kidney injury.
Important class effects follow directly from physiology. Reduced aldosterone signaling can increase potassium, and loss of angiotensin II-supported glomerular pressure can reduce filtration. ACE inhibitors can cause cough and, less commonly, angioedema through pathways involving bradykinin and other peptides. Spironolactone also interacts with sex-steroid receptors, accounting for effects such as gynecomastia. ACE inhibitors and ARBs are associated with fetal toxicity, particularly involving fetal kidney function, making pregnancy a major safety consideration. These differences prevent the classes from being treated as interchangeable forms of a single intervention.
Historical development and continuing research
The experimental history began in 1898, when Robert Tigerstedt and Per Bergman reported that rabbit kidney extracts produced a pressor response and named the active principle renin. The finding established that the kidney could influence blood pressure through a blood-borne substance, although the biochemical sequence remained unknown. In 1934, Harry Goldblatt and colleagues showed that constricting renal arteries in dogs could produce persistent hypertension. This connected impaired renal perfusion with a reproducible model of raised blood pressure and renewed interest in a renal pressor mechanism.
During the late 1930s and early 1940s, research groups led by Eduardo Braun-Menéndez in Argentina and Irvine Page in the United States independently characterized the pressor substance generated through renin’s action on a plasma substrate. The names hypertensin and angiotonin were eventually replaced by angiotensin. Subsequent work distinguished angiotensin I from angiotensin II and identified the converting step. Aldosterone was isolated and characterized in the early 1950s through work involving Sylvia Simpson, James Tait, Tadeus Reichstein, and collaborators. Jerome Conn’s 1955 description of primary aldosteronism connected autonomous adrenal hormone production with a recognizable hypertensive disorder.
The system became a practical therapeutic target through converging biochemical and pharmacological discoveries. Studies of peptides from the venom of the Brazilian pit viper, Bothrops jararaca, helped establish the feasibility of inhibiting ACE. Development of the orally active inhibitor captopril in the 1970s converted this principle into a widely usable medicine; it received United States approval in 1981. Subsequent development of selective AT1 antagonists made it possible to block angiotensin II signaling without inhibiting bradykinin breakdown. Large randomized controlled trials then established which molecular interventions improved clinical outcomes rather than merely changing blood pressure or laboratory measurements.
Discovery of ACE2 in 2000 expanded the biochemical model by identifying a distinct enzyme capable of processing angiotensin peptides. Interest in ACE2 increased further because it also serves as a cellular entry receptor for SARS-CoV and SARS-CoV-2. Its receptor role in viral infection and its enzymatic role in peptide metabolism are related to the same protein but are not equivalent processes. ACE inhibitors do not directly block ACE2, and mechanistic speculation about the system cannot by itself establish clinical effects in COVID-19.
Current research examines organ-specific signaling, nonsteroidal mineralocorticoid receptor antagonists, more selective aldosterone synthase inhibition, and long-acting methods of reducing hepatic angiotensinogen production. RNA-based approaches illustrate a shift from daily receptor or enzyme inhibition toward prolonged suppression of an upstream substrate. Their evaluation must address duration, reversibility, and the capacity to respond to acute illness or volume depletion, as well as blood-pressure effects. For tissue-specific and alternative angiotensin pathways, a continuing challenge is to connect experimental mechanisms with reproducible human outcomes rather than relying solely on peptide concentrations, cell studies, or animal models.